Fehmi Tabak
Overview
Explore the profile of Fehmi Tabak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
2099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ince Guliyev E, Sevgi D, Gunduz A, Mete B, Buyukgok D, Kumbasar Karaosmanoglu H, et al.
Int J STD AIDS
. 2024 Nov;
36(3):185-194.
PMID: 39560967
Objectives: Mental health (MH) care for people living with HIV (PLWH) emerges as an important unmet need, yet there are no integrated HIV-MH clinics in Turkey. Our aim is to...
2.
Cimen A, Celebi Torabfam G, Tok Y, Yucebag E, Arslan N, Saribal D, et al.
Bioanalysis
. 2024 Oct;
16(21-22):1167-1177.
PMID: 39411978
Serological studies with pseudotyped viruses offer a safer alternative to live SARS-CoV-2 in evaluating neutralizing antibodies, enabling research in standard labs. The SARS-CoV-2 Spike pseudotyped vesicular stomatitis virus (VSV) pseudoviruses...
3.
Resistance Genes and Mortality in Carbapenem-resistant Bacteremias: Effects of the COVID-19 Pandemic
Kurt A, Tanriverdi E, Yalcin M, Bayramlar O, Kaya S, Karaali R, et al.
Balkan Med J
. 2024 Aug;
41(5):357-368.
PMID: 39205634
Background: Emerging carbapenem-resistant () (CRKP) bacteremias are presenting significant public health risks due to limited treatment options and increased mortality. isolates exhibit carbapenem resistance rates that vary from 25% to...
4.
Yilmaz E, Kurt A, Dogruel M, Sevgi D, Kumbasar Karaosmanoglu H, Zerdali E, et al.
Curr HIV Res
. 2024 Aug;
22(4):266-269.
PMID: 39129162
Introduction: Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and...
5.
Alkan S, Balkan I, Surme S, Bayramlar O, Kaya S, Karaali R, et al.
Front Microbiol
. 2024 May;
15:1384392.
PMID: 38784804
Objective: Urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL) producing and are among the leading causes of morbidity and mortality in older adults. Identifying associated factors for ESBL production...
6.
Ozdemir Y, Ozdemir M, Bayramlar O, Kaya S, Karaali R, Balkan I, et al.
Biomark Med
. 2024 Jan;
17(19):799-809.
PMID: 38179991
Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. This was a retrospective, single-center study. The best area under the receiver operating characteristic ...
7.
Bakkaloglu O, Onal U, Eskazan T, Kurt E, Candan S, Karaali R, et al.
Singapore Med J
. 2023 Oct;
64(10):640-644.
PMID: 37861645
No abstract available.
8.
Kurt A, Cicek E, Alhelou T, Mete B, Karaali R, Kuskucu M, et al.
New Microbiol
. 2023 Sep;
46(3):311-314.
PMID: 37747478
T.marneffei, encountered mostly in Southeast Asia, leads to a systemic infection, especially in immunocompromised individuals such as HIV-infected patients with low CD4 level. A 32-year-old male patient, residing in Hong...
9.
Mete B, Kaya S, Kaya A, Kurt A, Bayramlar O, Karaali R, et al.
Turk J Gastroenterol
. 2023 Sep;
34(11):1163-1170.
PMID: 37681268
Background/aims: Discontinuation of nucleos(t)ide analog is controversial in HBeAg-negative chronic hepatitis B patients not achieved HBsAg loss. We aimed to evaluate re-treatment rates and risk factors in non-cirrhotic HbeAg-negative chronic...
10.
Modeling the future of HIV in Turkey: Cost-effectiveness analysis of improving testing and diagnosis
Yaylali E, Erdogan Z, Calisir F, Gokengin D, Korten V, Tabak F, et al.
PLoS One
. 2023 Jun;
18(6):e0286254.
PMID: 37390076
Aims: This study aimed to determine HIV incidence and prevalence in Turkey and to estimate the cost-effectiveness of improving testing and diagnosis in the next 20 years. Background: HIV incidence...